OR WAIT null SECS
Raja Atreya, MD, is head of the IBD Center at University Hospital of Erlangen.
November 17, 2026
Video
Raja Atreya, MD, reviews adverse events and treatment discontinuation through week 26 in the real-world UPlift study.
UPlift interim data show 70.2% achieved clinical response within 12 weeks, with a median time to first response of 13 days.
February 20, 2026
SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.